These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 28163543)

  • 1. Proprotein convertase subtilisin/kexin type 9 enzyme inhibitors: An emerging new therapeutic option for the treatment of dyslipidemia.
    Mazhar F; Haider N
    J Pharmacol Pharmacother; 2016; 7(4):190-193. PubMed ID: 28163543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in the Management of Dyslipidemia.
    Tziomalos K
    Curr Pharm Des; 2017; 23(10):1495-1499. PubMed ID: 28155622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [PCSK9 inhibitors: new treatment to lower cholesterol].
    Gencer B; Rodondi N; Mach F
    Rev Med Suisse; 2016 Mar; 12(508):440-2, 444. PubMed ID: 27089600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients.
    Zenti MG; Altomari A; Lupo MG; Botta M; Bonora E; Corsini A; Ruscica M; Ferri N
    Eur J Prev Cardiol; 2018 Nov; 25(17):1843-1851. PubMed ID: 30058841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness of alirocumab and evolocumab for the treatment of patients with diabetic dyslipidemia.
    Zhang J; Tecson KM; Rocha NA; McCullough PA
    Proc (Bayl Univ Med Cent); 2018 Apr; 31(2):180-184. PubMed ID: 29706812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Use of Monoclonal Antibody-Based Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors in the Treatment of Hypercholesterolemia.
    Parikh RR; Breve F; Magnusson P; Behzadi P; Pergolizzi J
    Cureus; 2022 Jun; 14(6):e25641. PubMed ID: 35795514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Injection of an improperly stored proprotein convertase subtilisin/kexin type 9 monoclonal antibody in a patient with secondary dyslipidemia from nephrotic syndrome: a case report.
    Kongmalai T; Chuanchaiyakul N; Srinoulprasert Y; Thongtang N
    J Med Case Rep; 2023 Mar; 17(1):89. PubMed ID: 36899379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PCSK9 inhibitors: monoclonal antibodies for the treatment of hypercholesterolemia.
    Paton DM
    Drugs Today (Barc); 2016 Mar; 52(3):183-92. PubMed ID: 27186592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Severe hypercholesterolaemia--when to use the proprotein convertase subtilisin-kexin type 9 protease inhibitors (PCSK9 inhibitors)? Polish Society of Cardiology experts' group statement].
    Cybulska B; Gaciong Z; Hoffman P; Jankowski P; Kłosiewicz-Latoszek L; Kaźmierczak J; Mitręga K; Opolski G; Pająk A; Ponikowski P; Rynkiewicz A; Stępińska J; Średniawa B; Kalarus Z
    Kardiol Pol; 2016; 74(4):394-8. PubMed ID: 27098076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An update on the clinical development of proprotein convertase subtilisin kexin 9 inhibitors, novel therapeutic agents for lowering low-density lipoprotein cholesterol.
    Ling H; Burns TL; Hilleman DE
    Cardiovasc Ther; 2014 Apr; 32(2):82-8. PubMed ID: 24354905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.
    Rey J; Poitiers F; Paehler T; Brunet A; DiCioccio AT; Cannon CP; Surks HK; Pinquier JL; Hanotin C; Sasiela WJ
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27287699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alirocumab: targeting PCSK9 to treat hypercholesterolemia.
    Pećin I; Reiner Ž
    Drugs Today (Barc); 2015 Dec; 51(12):681-7. PubMed ID: 26798848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.
    Agabiti Rosei E; Salvetti M
    High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.
    Desai NR; Kohli P; Giugliano RP; O'Donoghue ML; Somaratne R; Zhou J; Hoffman EB; Huang F; Rogers WJ; Wasserman SM; Scott R; Sabatine MS
    Circulation; 2013 Aug; 128(9):962-9. PubMed ID: 23884353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report.
    Thedrez A; Sjouke B; Passard M; Prampart-Fauvet S; Guédon A; Croyal M; Dallinga-Thie G; Peter J; Blom D; Ciccarese M; Cefalù AB; Pisciotta L; Santos RD; Averna M; Raal F; Pintus P; Cossu M; Hovingh K; Lambert G
    Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1647-50. PubMed ID: 27079874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.
    Achimastos A; Alexandrides T; Alexopoulos D; Athyros V; Bargiota A; Bilianou E; Chrysochoou C; Drogari E; Elisaf M; Ganotakis E; Goudevenos I; Ioannidis I; Kolovou G; Kotsis V; Lekakis I; Liberopoulos E; Melidonis A; Nikolaou V; Ntaios G; Papanas N; Pappas S; Pitsavos C; Rallidis L; Richter D; Skoumas I; Tentolouris N; Tousoulis D; Tselepis A; Tsioufis K; Tziakas D; Tziomalos K; Vardas P; Vlachopoulos C; Vlahakos D
    Hormones (Athens); 2016; 15(1):8-14. PubMed ID: 27086681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proprotein convertase subtilisin/kexin type 9 inhibitors for reduction of cardiovascular events.
    Turgeon RD; Pearson GJ
    Am J Health Syst Pharm; 2018 Jun; 75(11):747-754. PubMed ID: 29802110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab.
    Desai NR; Giugliano RP; Wasserman SM; Gibbs JP; Liu T; Scott R; Sabatine MS
    JAMA Cardiol; 2017 May; 2(5):556-560. PubMed ID: 28122070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PCSK9 inhibitors - from discovery of a single mutation to a groundbreaking therapy of lipid disorders in one decade.
    Jaworski K; Jankowski P; Kosior DA
    Arch Med Sci; 2017 Jun; 13(4):914-929. PubMed ID: 28721159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.